Nakagawa and colleaguesobserved that tumor-secreted (not stromal secreted) HGF could induce resistance to theVEGFR inhibitor lenvatinib, and that this resistance could be overcome by co-treatmentwith golvatinib, a MET inhibitor (Nakagawa et al.,2014). This evidence concerns the gene HGF and neoplasm.